推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

DRUG SAFETY

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 DRUG SAFETY最新评论:我也是什么情况呀呜呜 (2024-09-10)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
 
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


DRUG SAFETY期刊基本信息Hello,您是该期刊的第26943位访客


基本信息 登录收藏
期刊名字DRUG SAFETYDRUG SAFETY

DRUG SAFETY
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
6.4
51人评分
我要评分

声誉
7.6

影响力
5.3

速度
7.1

期刊ISSN0114-5916
微信扫码收藏此期刊
E-ISSN1179-1942
2023-2024最新影响因子
(数据来源于搜索引擎)
4 点击查看影响因子趋势图
实时影响因子 截止2024年10月29日:2.607
2023-2024自引率7.50%点击查看自引率趋势图
五年影响因子4.1
JCI期刊引文指标 1.01
h-index 115
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
7.601.2041.277
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q144 / 272
大类:Medicine
小类:Toxicology
Q123 / 133
大类:Medicine
小类:Pharmacology
Q281 / 313

期刊简介
Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:

Overviews of contentious or emerging issues.
Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.
In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area.
Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
Editorials and commentaries on topical issues.
Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
期刊官方网站https://www.springer.com/40264
期刊投稿网址https://www.editorialmanager.com/drsa
作者指南网址https://www.springer.com/40264/submission-guidelines
期刊语言要求Language
Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足DRUG SAFETY的语言要求,还能让DRUG SAFETY编辑和审稿人得到更好的审稿体验,让稿件最大限度地被DRUG SAFETY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311
出版商Springer International Publishing
涉及的研究方向医学-毒理学
出版国家或地区NEW ZEALAND
出版语言English
出版周期Monthly
出版年份1986
年文章数 96点击查看年文章数趋势图
Gold OA文章占比54.20%
研究类文章占比:
文章 ÷(文章 + 综述)
91.67%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:1区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ182/354
学科:PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTHSCIEQ156/403
学科:TOXICOLOGYSCIEQ122/106
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ180/354
学科:PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTHSCIEQ195/403
学科:TOXICOLOGYSCIEQ122/106
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区2区1区
PHARMACOLOGY & PHARMACY
药学
4区1区2区
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
公共卫生、环境卫生与职业卫生
3区3区2区
TOXICOLOGY
毒理学
3区1区2区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 3区2区3区
PHARMACOLOGY & PHARMACY
药学
3区4区2区
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
公共卫生、环境卫生与职业卫生
3区3区2区
TOXICOLOGY
毒理学
4区3区2区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 2区2区2区
TOXICOLOGY
毒理学
4区4区1区
PHARMACOLOGY & PHARMACY
药学
3区1区2区
PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
公共卫生、环境卫生与职业卫生
2区3区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0114-5916%5BISSN%5D
平均审稿速度网友分享经验:
较慢,6-12周
平均录用比例网友分享经验:
一般
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在DRUG SAFETY顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 DRUG SAFETY期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 DRUG SAFETY中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
DRUG SAFETY上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    DRUGS15422.70
    Annual Review of Pharmacology and Toxicology19327.80
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS7013.80
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH11412.20
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY11012.10
    Reviews of Environmental Contamination and Toxicology6512.80
    CRITICAL REVIEWS IN TOXICOLOGY989.50
    CELL BIOLOGY AND TOXICOLOGY569.90
    ARCHIVES OF TOXICOLOGY9611.60
    TOXICOLOGY1437.80
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE677320
    BIOMATERIALS567016
    BIOMEDICINE & PHARMACOTHERAPY551721
    Frontiers in Pharmacology515525
    Journal of Materials Chemistry B506403
    Frontiers in Immunology492230
    COMPUTERS IN BIOLOGY AND MEDICINE474054
    JOURNAL OF ETHNOPHARMACOLOGY466427
    COLLOIDS AND SURFACES B-BIOINTERFACES438646
    Frontiers in Oncology436282
  •  

    DRUG SAFETY DRUG SAFETY
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes

    Author: Lui, David Tak Wai; Wu, Tingting; Au, Ivan Chi Ho; Liu, Xiaodong; Fung, Matrix Man Him; Lee, Chi Ho; Fong, Carol Ho Yi; Woo, Yu Cho; Lang, Brian Hung Hin; Tan, Kathryn Choon Beng; Wong, Carlos King Ho
    Journal: DRUG SAFETY. 2023; Vol. 46, Issue 1, pp. 53-64. DOI: 10.1007/s40264-022-01247-3
        PubMed      DOI
    2.Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition

    Author: Minjie Lin, Shuiping Zhao, Li Shen, Danyan Xu
    Journal: DRUG SAFETY, 2014, Vol.37, 213-224, DOI:10.1007/s40264-014-0147-x
        DOI
    3.Dosage Effects of Histamine-2 Receptor Antagonist on the Primary Prophylaxis of Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated Peptic Ulcers: A Retrospective Cohort Study

    Author: Ying He, Esther W. Chan, Kenneth K. C. Man, Wallis C. Y. Lau, Wai K. Leung, Lai M. Ho, Ian C. K. Wong
    Journal: DRUG SAFETY, 2014, Vol.37, 711-721, DOI:10.1007/s40264-014-0209-0
        DOI
    4.Pharmacovigilance in China: Current Situation, Successes and Challenges

    Author: Li Zhang, Lisa Y. L. Wong, Ying He, Ian C. K. Wong
    Journal: DRUG SAFETY, 2014, Vol.37, 765-770, DOI:10.1007/s40264-014-0222-3
        DOI
    5.Anti-Tuberculosis Drug-Induced Liver Injury in Shanghai: Validation of Hy’s Law

    Author: Xin Shen, Zheng’an Yuan, Jian Mei, Zurong Zhang, Juntao Guo, Zheyuan Wu, Jie Wu, Haihua Zhang, Jieping Pan, Wenming Huang, Huili Gong, Dong Yuan, Ping Xiao, Yanqin Wang, Yi Shuai, Senlin Lin, Qichao Pan, Tong Zhou, Paul B. Watkins, Fan Wu
    Journal: DRUG SAFETY, 2013, Vol.37, 43-51, DOI:10.1007/s40264-013-0119-6
        DOI
    6.Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants

    Author: Haixia Li, Cailian Wang, Shuo Zhang, Sihao Sun, Ruifei Li, Meijuan Zou, Gang Cheng
    Journal: DRUG SAFETY, 2016, Vol.39, 409-419, DOI:10.1007/s40264-016-0394-0
        DOI
    7.National ADR Monitoring System in China

    Author: Yongfang Hou, Xinling Li, Guizhi Wu, Xiaofei Ye
    Journal: DRUG SAFETY, 2016, Vol.39, 1043-1051, DOI:10.1007/s40264-016-0446-5
        DOI
    8.Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature

    Author: xiongbiao6
    Journal: DRUG SAFETY, 2016.
    9.Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants

    Author: chenggang63
    Journal: DRUG SAFETY, 2016.
    10.Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants

    Author: chenggang63
    Journal: DRUG SAFETY, 2016.
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    Living Reviews in Relativity069.90
    Living Reviews in Relativity7569.90
    Advanced Composites and Hybrid Materials026.00
    Kidney International Supplements2026.70
    Kidney International Supplements2426.70
    Wiley Interdisciplinary Reviews-Computational Molecular Science6228.90
    Military Medical Research038.40
    NUCLEIC ACIDS RESEARCH45227.10
    Environmental Chemistry Letters5032.00
    Journal of the National Comprehensive Cancer Network8820.20
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共4


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室